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Abstract
Behçet’s disease (BD), a chronic vasculitis affecting any type of the blood vessels, was 
first described by a Turkish dermatologist Hulusi Behçet. Although it has a worldwide 
distribution, it is commonly seen in the Silk Road countries around the Mediterranean 
Sea. The country in which the disease is most commonly seen is Turkey with a prevalence 
of 20–602/100,000. The disease most appears between the second and fourth decades of 
the life. BD affects both genders equally. However, the gender distribution may differ 
among different regions.
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1. Introduction
Behçet’s disease (BD) is a chronic multisystem vasculitis, which affects any type and shape 
of blood vessels, particularly veins [1, 2]. The disease was first described in 1937 by a Turkish 
dermatologist, Hulusi Behçet, as a triple symptom complex, aphthous stomatitis, genital 
ulcers and relapsing uveitis [3]. Most widely used classification criteria is suggested by The 
International Study Group (ISG) for BD in 1990 [4]. According to the ISG, the major crite-
rion exactly required for the diagnosis is recurrent oral ulceration at least three times a year. 
Additionally, at least two of the minor criteria: genital ulceration, skin lesions (erythema nodo-
sum, necrotic folliculitis, and papulopustular lesions), ocular lesions (posterior uveitis, total 
uveitis, and retinal vasculitis), and positive pathergy testing are required for the diagnosis [4].
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. Epidemiology
2.1. Prevalence
BD has a worldwide distribution. But it is commonly seen in the Silk Road countries around 
the Mediterranean Sea, including Spain, Portugal, Turkey, Iran, and Far East countries like 
China and Japan [5, 6]. The prevalence of the disease along the silk route is 14–20/100,000 [7]. 
BD is most common in Turkey with the prevalence of 20–602/100,000 [8, 9]. The other more 
prevalent countries are Iran, China, Tunisian, Korea, Israel, and Japan [8, 10, 11]. In North 
European, American, and African countries BD is less frequent [12, 13]. The prevalence of BD 
in some countries is shown in Table 1 [8, 9, 12, 14–20].
Since 1982, the supported hypothesis about the etiopathogenesis of BD has been that the 
genetic material and the exogenous agents responsible for the disease were carried during 
the immigration of ancient nomadic tribes [15]. Many studies focus on immigrations so far 
have investigated how the genetic or environmental factors affect the development of BD. In 
1997 in Germany, 218 patients with BD were investigated. Of these patients, 89 were German, 
100 were Turkish, and 29 were from other nationalities. The prevalence of BD was found 
0.16/100,000 in German population and 4.51/100,000 in Turkish population. The prevalence 
of BD in Turkish population was higher than German population. However, it was 5–18-fold 
lower than the prevalence found in Turkey. This study suggested that the genetic and envi-
ronmental factors are both effective in the development of the disease [15]. Another similar 
study was performed in 2015 in the Rotterdam area of Netherland [5]. Eighty-four patients of 
Dutch, Turkish, or Moroccan origin with BD were identified. The prevalence of BD was found 
1/100,000 in Dutch, 71/100,000 in Turkish and 39/100,000 in Moroccan population. The study 
mentioned that the prevalence of BD in different ethnic group was similar to that among the 
Country Prevalence (1/100,000)
Turkey [8, 9] 20–602
Israel [14, 15] 50–185
Iran [12, 16] 16.7–100
Iraq [17] 17
Japan [9] 7–13.5
China [18] 2.62
Kuwait [12] 2.1
Italy [19, 20] 4.1–15.9
Germany [21] 0.9
USA [12] 0.33
Table 1. Worldwide prevalence of Behçet’s disease.
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original countries of these patients. However, another study reported that no patient with BD 
was detected in Hawaii, where the Japan population is relatively high [11].
2.2. Age and gender
Behçet’s disease can be seen at any age, but it mostly appears between the second and fourth 
decades of life [22]. In a study from Ankara, Turkey, the mean age of the patients with BD was 
found 37.2 [23]. In a study from Japan, the mean age of onset was found 36.8 [24]. The mean 
age of onset of BD in many countries was shown in Table 2 [5, 13, 15, 23–34].
Regional and ethnic factors may affect the time of the diagnosis of the illness. The diagnosis 
of the disease is delayed in areas where the prevalence of the disease is lower [12]. In a study 
from Germany, it was reported that the time of diagnosis of BD in Turkish patients was earlier 
than in German patients. The diagnosis was later and more difficult in German patients than 
in Turkish patients, so that we should keep in mind that some German patients might be fol-
lowed with wrong diagnosis for long times before the diagnosis of BD [15, 35].
Patients with earlier onset have more severe disease [36]. In a study from Tunisia, BD patients 
with onset before age of 20 and after age of 40 were compared each other. Cutaneous involve-
ment, pseudo folliculitis, and vena cava thrombosis were more frequent in patients with ear-
lier onset. In contrast, joint involvement was more frequent in patients with later onset [28]. 
Mortality in the group with earlier onset was 2.46% but no patients had died due to BD in 
the group with later onset [28]. Some authors reported that BD patient with earlier onset had 
more ophthalmic manifestations and active course of the disease [37, 38].
Country Age of onset Male/female
Turkey [23, 25] 37.2–38.02 0.69–1.03
Japanese [24] 36.8 0.74
Iran [26] 26.2 1.4
Israel [27] 34.9 1.22
Netherlands [5] 43 0.64
Senegal [13] 32 1.6
Tunisian [28] 29.12 2.1
Germany [15, 29] 24.5–27.4 1.51–1.38
Saudi Arabia [30] 29.3 3.4
China [31] 35.8 1.4
Italy [32] 33 1
England [33] 32 0.96
USA [34] 29.25 0.3
Table 2. Age and gender ratio distribution among countries.
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Clinical features (%) Kone-paut 
[42]
Kone-paut 
[41]
Krause 
[44]
Karıncaoğlu 
[45]
Atmaca 
[46]
Eldem 
[47]
Uziel 
[48]
Allali 
[40]
N (patients) 65 55 19 33 110 20 15 12
Oral aphthosis 96 100 100 100 100 100 100 100
Genital aphthosis 70 79 31.9 82 83 65 33 75
Cutaneous findings 92 78 89.5 52 76 35 93 16.7
Pathergy test + – – 41.2 37 45.5 – 40 58
Ocular signs 60 87 47.4 35 31 80 53 53
Articular findings 56 17 47.4 40 22 40 73 25
Gastrointestinal 
findings
14 – 36.8 – 5 46 8.3
Neurological findings 15 10 26.3 7.2 3.6 15 4 40
Vascular findings 15 21 10.5 9.6 3.6 5 0 33.3
Table 3. Clinical features of pediatric BD.
BD is uncommon in children. Patients with initial symptoms at age 16 years or lower are classi-
fied as juvenile-onset BD [39]. The prevalence of juvenile BD is unknown. However, in few series, 
it was reported that 3.3 and 26% of the patients with BD were juvenile-onset BD [2]. The clinical 
symptoms are not different from adults but the diagnosis may be delayed in pediatric patients 
because of mild symptoms [2]. Juvenile onset patients had more familial cases compared with 
adult-onset patients [39]. There are some different series presenting juvenile BD. In the study of 
Allali et al., one-third of the patient had family history [40]. In the series of Kone-Paut et al., fam-
ily history was reported as 9 and 24.4%. But in adults, family history was found as 2.2% [41–43]. 
The clinical features of juvenile BD in different series are seen in Table 3 [40–42, 44–48].
BD disease affects both the gender equally [12]. But the gender distribution may differ between 
different regions. A few studies showed that male predominance was seen in Middle Eastern 
countries, while female predominance was seen in Asian countries [1]. The male/female ratios 
from the studies are shown in Table 2.
Gender affects the clinical findings and the severity of the disease as well [12]. In a long-term 
study performed by Kural-Seyahi et al., it was implicated that the disease is more severe in 
male patients, and vascular disease might be the major risk factor of death in male patients 
[49]. Saadoun et al. supported that male sex, arterial involvement and a high number of BD 
flares were independently associated with the risk of mortality [50]. In 2015, Bonitsis et al. 
presented a meta-analysis of the gender-specific differences in BD. They investigated both 
the German registry of BD and systematic literature review meta-analysis (52 other pub-
lications from Turkey, Asia, Southern Europe, Northern Europe, South America, the USA, 
and North Africa/Middle East) [29]. They found that vascular disease (superficial and deep 
venous thrombosis and heart involvement), folliculitis, papulopustular skin lesions, positive 
pathergy test and ocular disease are more common in males, while erythema nodosum, geni-
tal ulcers and joint involvement are more common in females [29].
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2.3. Epidemiology of clinical findings
Regional and environmental factors may affect clinical findings of BD. Prevalence of differ-
ent clinical findings may differ among the patients from different regions [12]. Frequency 
of presence of oral aphthosis is almost same in patients from all regions with the rate of 
96–100% [1, 12]. In Japan, 4.6–15% of endogen causes of uveitis are BD [13, 51]. In a study 
from Japan, 69% of the patients had ocular findings [52]. But uveitis is quite rare in Australia 
[1]. Neurological features are more common in Caucasians (23%) than Middle Eastern 
series (3–10%) and frequency of seizures was found to be higher than Turkish series (27 
and 5%, respectively) [53]. Another study detected that Sub-Saharan African BD patients 
had a higher frequency of CNS involvement compared to North African and European BD 
patients [54]. Intestinal BD is rare in Mediterranean countries but it is more common in 
Japanese BD patients [12]. Clinical findings of patients from different regions are shown in 
Table 4 [13, 23, 24, 28–30, 55].
2.4. Pathergy reaction
Pathergy reaction is a nonspecific skin hyper reactivity to minor trauma. Positivity is defined 
as occurring of a papule or pustule, 24–48 h after intradermal injection of skin with 20 gauge 
needle [1]. Positive pathergy test is one of the diagnosis criteria of BD [4]. The pathergy 
reaction is highly sensitive and specific for BD in patients from Silk Road countries like 
Turkey, from some Mediterranean, the Middle Eastern countries and Japan. However, it is 
rarely observed in patients from Northern Europe, USA and Australia [1, 56]. Although the 
pathergy test lost its sensitivity during the past 35 years, it is still a valuable diagnostic test 
[57]. Some studies from Japan and Turkey have reported a decrease in the positive pathergy 
reaction in BD [56]. In 1979, the skin pathergy positivity rate was found 84% in patients 
with BD in a study from Turkey [58]. In another study from Turkey in 1991, the rate was 
found 65% [59]. In a more recent study from Turkey, the rate of pathergy test positivity was 
Country Oral 
ulcer
Genital 
ulcer
Skin 
findings
Ocular 
findings
Articular 
findings
Vascular 
findings
Gastroin-
testinal 
findings
Neurological 
findings
Pulmonary 
findings
Pathergy 
test +
Turkey [23] 100 73 52 40 22 9.6 1 3.5 2.6 39
Germany 
[29]
99.7 72.8 79.9 50.4 54.1 22.4 11.5 12.1 1.3 28.5
Senegal 
[13]
100 96 30 44 40 18 2 24 – 32
Japan [24] 99 72.3 88.8 61.6 52.1 8.0 12.3 10.2 – –
Iran [55] 97.5 65.7 64.6 58.1 39.4 9.1 7 10.6 1 52.3
Saudi 
Arabia [30]
100 87 57 65 37 25 4 44 – 17.5
Tunisia [28] 100 85 74.4 46.5 45.7 34.9 7 32.6 – 57.7
Table 4. Clinical findings of BD among some countries.
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detected as 39% [23]. The decrease of pathergy test positivity rate can be also seen in some 
Japanese studies. In a study  from Japan in 1972 the rate of positive pathergy test was found 
75%, while in an other study performed in 2011 this rate was found %50 [56]. These differ-
ences may be occurred due to different applying techniques. One of the important methods 
is using non-disposable/blunt needles. In 2000, it was reported that clinical evaluation of 
the pathergy test conducted intradermally with non-disposable/blunt needles is sufficient 
for both the diagnosis and determination of the activation of Behçet’s disease [60]. Also it is 
shown that surgical cleaning of the test area before needle prick reduced the prevalence of 
pathergy test positivity rate [61]. This information suggests that the positive reaction might 
be a cutaneous response to some bacteria living on the surface of the skin. In a recent study, 
performed by Togashi et al. suggested that a new diagnostic pathergy test may solve the 
methodological problems [62]. They performed a skin prick test with filter-sterilized saliva 
on forearm skin. Of the patients with BD, 90% showed indurative erythema at the skin site 
pricked with self-saliva, and 60% of recurrent aphthous stomatitis patients showed weak 
reaction. They suggested that skin prick test using self-saliva can be a diagnostic test for dif-
ferentiating BD from other mucocutaneous diseases [62].
The reactivity of the pathergy test is suggested to be correlated with HLA-B51 in Mediterranean 
countries [63]. Rates of pathergy positivity from different studies are shown in Table 4 [13, 
23, 24, 28–30, 55].
2.5. Genetic factors and epidemiology
Although familial cases were reported, a Mendelian inheritance model specific to BD is not 
present [12]. In the western series, familial case rates were as follows: 0.7–2.7% in Italy, 3.6% 
in England and 4.5% in Portugal. The familial case rates were 11.9–13.4% in the studies from 
Tunisia, Israel, and Korea studies [12, 15, 64]. In a study from Turkey, family history was 
reported as 31.2% [65]. Multiple studies have demonstrated that BD is strongly associated 
with the presence of HLA-B5 and its split antigen HLA-B51 [12, 66]. The association with 
HLA-B5 was first described by Ohno et al. in 1973 [56]. The genetic material of the BD might 
be carried in parallel with population movement between the Mediterranean and Asia. 
Supporting this content is that the distribution areas of this antigen among healthy control 
populations are the ancient trade route and the region in which BD is commonly seen [67]. 
HLA-B51 frequency is high in the Mediterranean countries but it is low in western countries 
like USA and England [12]. In recent studies, many new genes other than HLA-B51 (IL-10 sig-
naling pathways, IL6–174 G/C, MMP-9, CLEC16A, NKFB1, IL-23 receptor gene, IL-18, IL-6, 
IL10, Vitamin D receptor, etc.) associated with BD were also identified [36]. Shigemura et al. 
studied on six patients over four generations with BD in 2016, and they found a common 
heterozygous missense mutation in A20/TNFAIP3; a gene known to regulate NF-κB signal-
ing. Mutation in A20/TNFAIP3 was likely responsible for increased production of human 
inflammatory cytokines by reduced suppression of NF-κB activation. They suggested that 
this mutation may lead to the autosomal-dominant Mendelian mode of BD transmission in 
this family [68].
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3. Conclusion
BD has a worldwide distribution. But it is commonly observed along the Silk Road countries 
between the Mediterranean Sea. It is most common in Turkey. The prevalence of the disease, 
the frequency of the clinical findings, and genetics may differ between different regions. The 
disease is more severe among males than females. Diagnosis of BD is difficult, and the disease 
must be recognized, because early diagnosis is important for the early treatment.
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